Unlock this StockReport nowClick to Unlock

Selvita SA Share Price

SLV PLN55.6 0.8  1.5%

Relative Strength (%)
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
Margin of Safety (beta)
Screens Passed
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Dec 2012 2013 2014 2015 2016 2017 TTM 2018E 2019E CAGR / Avg
Revenue PLNm
Operating Profit PLNm
Net Profit PLNm
EPS Reported PLN
EPS Normalised PLN
EPS Growth %
PE Ratio x
Operating Margin %
Op. Cashflow ps PLN
Capex ps PLN
Free Cashflow ps PLN
Dividend ps PLN
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc PLNm
Working Capital PLNm
Net Fixed Assets PLNm
Net Debt PLNm
Book Value PLNm
Average Shares m
Book Value ps PLN +51.9%

FINANCIAL BRIEF: For the nine months ended 30 September 2018, SELVITA SA revenues increased 17% to PLN56.6M. Net income increased 44% to PLN12.8M. Revenues reflect Services segment increase from PLN10.9M to PLN43M, Bioinformatic segment increase from PLN1.7M to PLN5.7M, Innovative segment increase of 83% to PLN8M. Net income benefited from Services segment income increase from PLN1.7M to PLN6.8M, Bioinformatic segment income increase from PLN353K to PLN990K. more »

Health Trend
Bankruptcy Risk
  Earnings Manipulation Risk
Magic Formula Score
Other Ratios
Leverage (ttm) Total -Intang +Pension
Gross Gearing %
Net Gearing %
Cash / Assets %
Recent History
Latest interim period (ended 30th Sep '18) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Dec 2018
31st Dec 2019

Price Target: N/A
Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: n/a (PLN) (PLN) (PLN) (PLN) (PLN) (PLN)
Consensus Estimate
1m Change
3m Change
2 brokers Broker Consensus Trend
Broker Recommendations for Selvita SA
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts:

Named Brokers and Analysts
Edison Investment Research Jonas Peciulis , Vestor Dom Maklerski Beata Szparaga-Wasniewska ,

Profile Summary

Selvita SA is a Poland-based company engaged in the healthcare industry. The Company is active in the pharmaceutical and biotechnology fields. It operates through two business segments. The Innovative segment develops new drugs mainly for oncology and central nervous system diseases. The Services segment is engaged in the research and development activities, such as introducing substances on the market, client service and reducing the risk. The Company’s portfolio encompasses projects, including kinesis inhibitors platform, the platform of the metabolism for the cancer and epigenetic, among others. Selvita SA is active in the domestic market and internationally, such as in the United States. It operates through unit Ardigen SA and SORS Holdings Ltd.

Directors: Piotr Romanowski (CSU) , Pawel Przewiezlikowski (CMG) 45, Tadeusz Wesolowski (VSU) , Krzysztof Brzozka (VMG) , Boguslaw Sieczkowski (VMG) , Milosz Gruca (MGB) , Edyta Jaworska (MGB) , Miroslawa Zydron (MGB) , Wojciech Chabasiewicz (IND) , Rafal Chwast (IND) , Wojciech Sobieraj (SUB) ,

No. of Employees: 431 No. of Shareholders: n/a

Last Annual December 31st, 2017
Last Interim September 30th, 2018
Incorporated October 6, 2010
Public Since July 14, 2011
Shares in Issue 15,971,229
Free Float 10.1m (63.0%)
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange Warsaw Stock Exchange
Eligible for an ISA? a SIPP?

SLV Share Price Performance SLV Share Price Quote
0.8  1.5%
Traded 4:35pm · Minimum 15 min delayed · NMS:

Latest SLV News Announcements (delayed)

Upcoming SLV Events
Tuesday 14th May, 2019 (estimate)
Selvita SA Annual Shareholders Meeting

Recent ↓
Monday 14th May, 2018
Selvita SA Annual Shareholders Meeting
Tuesday 29th August, 2017
Selvita SA Annual Shareholders Meeting
Monday 19th June, 2017
Selvita SA Annual Shareholders Meeting
Tuesday 25th April, 2017
Selvita SA Secondary Public Offering Filing
Tuesday 25th October, 2016
Selvita SA Annual Shareholders Meeting

Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2019.

Should you buy SLV

Access SLV Analytics Now!

Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis